From designing algorithms to analyzing their efficiency, understanding these core concepts is key to solving problems in ...

ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

So, you’re looking to get better at coding interviews, huh? Maybe you’ve heard about LeetCode and feel a bit lost. It’s ...

We’re being sold a world where there’s no room for reflection or spontaneity. This is the Black Mirror stage of capitalism, says Alexander Hurst, who writes for Guardian Europe from Paris ...

Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

new video loaded: I’m Building an Algorithm That Doesn’t Rot Your Brain transcript “Our brains are being melted by the algorithm.” [MUSIC PLAYING] “Attention is infrastructure.” “Those algorithms are ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...